Age is one of the strongest risk factors for breast cancer: nearly half of new cases occur in women 65 or older, and about 20% in those 75 and up. Yet older women are often left out of clinical trials, leaving doctors with limited evidence on how treatments work in this group. Neil Carleton, a cancer biologist and first-year resident at Brigham and Women’s Hospital, argues that breast tumors in older patients can behave differently due to hormone levels and inflammation, and that care should be tailored rather than
Tailoring breast cancer care for older women: a physician’s push
Neil Carleton is working to move beyond 'age-agnostic' breast cancer care, from electronic health record nudges to understanding tumor biology in older patients.
More in Medicine & Biotech
Epilepsy drug lacosamide shows promise for osteoarthritis cartilage repair
A Yale study suggests an FDA-approved epilepsy drug, delivered via hydrogel, may both ease pain and reverse cartilage damage in osteoarthritis.
Dr. Mike for 'The Bachelor,' AAP Antics, and Plague Context
A roundup of healthcare social media moments, from a reality TV rumor to pediatricians' conference antics and plague context.
NIH Funding Uncertainty Stymies U.S. Researchers
A STAT podcast examines how unpredictable NIH spending is disrupting biomedical research and feeding biotech investor gloom.
FDA Flags Safety Signal After Four Deaths in Evenamide Schizophrenia Trials
Four deaths among evenamide-treated patients have prompted FDA safety concerns and a continued U.S. enrollment hold in a phase III schizophrenia trial.